Valeo Pharma Inc. (C:VPH)
Business Focus: Pharmaceuticals (NEC)
| Sector: Healthcare | Industry: Pharmaceuticals |
| Company Contact | |
| Address: | 16667 Hymus Blvd KIRKLAND QC H9H 4R9 |
| Tel: | 1-514-7828803 |
| Website: | https://valeopharma.com |
| IR: | See website |
| Key People | ||
| Richard J. MacKay Chairman of the Board | Steven Saviuk President, Chief Executive Officer, Director | Luc Mainville Chief Financial Officer, Senior Vice President |
| Nelly Komari Senior Vice President - Scientific and Medical Affairs | Kyle Steiger Senior Vice President, Chief Commercial Officer | Helen Saviuk Vice President - Operations |
| Guy Paul Allard Vice President - Legal Affairs, Corporate Secretary | Nathalie Therrien Vice President - Quality Assurance and Regulatory Affairs | Jeff Skinner Vice President - Business Development |
| Business Overview |
| Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc. |
| Financial Overview |
| For the three months ended 31 January 2024, Valeo Pharma Inc revenues increased 3% to C$13.5M. Net loss increased 10% to C$6.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest on debentures increase of 45% to C$750K (expense), Selling/General/Admin Expense increase of 35% to C$797K (expense). |
| Employees: | 100 as of Jan 31, 2024 |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $68.48M as of Jan 31, 2024 |
| Annual revenue (TTM): | $54.29M as of Jan 31, 2024 |
| EBITDA (TTM): | -$15.57M as of Jan 31, 2024 |
| Net annual income (TTM): | -$28.43M as of Jan 31, 2024 |
| Free cash flow (TTM): | -$8.40M as of Jan 31, 2024 |
| Net Debt Last Fiscal Year: | $56.16M as of Jan 31, 2024 |
| Shares outstanding: | 98,675,427 as of Mar 13, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
